Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
Recent Articles
RELATED ARTICLES
-
Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
- NEWS WRAP: Ribo Life enters Hong Kong biotech fast lane after strong debut
- A healthy return: drug spin-off nets Keymed up to $320 million
-
Huaqin stock rises in Hong Kong debut as AI data center business booms
3296.HK603296.SHG
